31.48MMarket Cap-2.77P/E (TTM)
8.185High7.800Low3.16KVolume8.000Open8.240Pre Close25.11KTurnover0.31%Turnover RatioLossP/E (Static)3.97MShares19.00052wk High-1.61P/B8.06MFloat Cap4.56052wk Low--Dividend TTM1.02MShs Float221.550Historical High--Div YieldTTM4.67%Amplitude4.560Historical Low7.936Avg Price1Lot Size
MiNK Therapeutics Stock Forum
MiNK's Breakthrough: 80% Patient Survival Rate Powers Financial Turnaround
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...
$CN Energy (CNEY.US)$ 0.2919-0.4512 = 54.57% RUNNER
$Cheetah Net Supply Chain Service (CTNT.US)$ 1.96-2.37 = 20.92%
$Golden Sun Health Technology (GSUN.US)$ 2.35-5.25 = 123% MEGA RUNNER
$MicroCloud Hologram (HOLO.US)$ 1.508 - 1.94 = 28.65%
$MiNK Therapeutics (INKT.US)$ 9.99-12 = 20.12%
$iSpecimen (ISPC.US)$ 2.06-3.03...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press rele...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
Thursday, 20th February at 7:30 am
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal ...
Groundbreaking Gastric Cancer Trial Results: MiNK's Triple Therapy Approach Takes Center Stage at AACR
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Wednesday, 12th February at 1:00 pm
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you ...
No comment yet